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Abstract
In the course of breast cancer global gene expression studies, we identified an uncharacterized gene
known as RHBDD2 (Rhomboid domain containing 2) to be markedly over-expressed in primary
tumors from patients with recurrent disease. In this study, we identified RHBDD2 mRNA and protein
expression significantly elevated in breast carcinomas compared with normal breast samples as
analyzed by SAGE (n=46) and immunohistochemistry (n=213). Interestingly, specimens displaying
RHBDD2 over-expression were predominantly advanced stage III breast carcinomas (p=0.001).
Western-blot, RT-PCR and cDNA sequencing analyses allowed us to identify two RHBDD2
alternatively spliced mRNA isoforms expressed in breast cancer cell lines. We further investigated
the occurrence and frequency of gene amplification and over-expression affecting RHBDD2 in 131
breast samples. RHBDD2 gene amplification was detected in 21% of 98 invasive breast carcinomas
analyzed. However, no RHBDD2 amplification was detected in normal breast tissues (n=17) or breast
benign lesions (n=16) (p=0.014). Interestingly, siRNA mediated silencing of RHBDD2 expression
results in a decrease of MCF7 breast cancer cells proliferation compared with the corresponding
controls (p=0.001). In addition, analysis of publicly available gene expression data showed a strong
association between high RHBDD2 expression and decreased overall survival (p=0.0023), relapse-
free survival (p= 0.0013), and metastasis-free interval (p=0.006) in patients with primary ER-
negative breast carcinomas. In conclusion, our findings suggest that RHBDD2 over-expression
behaves as an indicator of poor prognosis and may play a role facilitating breast cancer progression.
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INTRODUCTION
In the course of recent breast cancer global gene expression studies we identified a distantly
related rhomboid-like gene known as RHBDD2 (Rhomboid domain containing 2) located at
the 7q11.23 chromosomal region, to be markedly over-expressed in primary invasive
carcinomas from patients that recurred within 6 years of follow-up (1).
The human genome contains several rhomboid-like genes which can be phylogenetically
grouped in three major classes (2). The first class, includes the true active rhomboids genes
that are subdivided into secretase (e.g. RHBDL-1/-2/-3 and RHBDD1 genes) and PARL-type
subfamilies. The second class is composed by novel inactive rhomboids members, recently
names as iRhoms group (e.g. RHBDF-1/-2 genes). The third group includes a small number
of other distant evolutionary related and uncharacterized genes (e.g. RHBDD-2/-3) for which
there are no evidence that they are active proteases. Rhomboid-like proteins function in diverse
processes including quorum sensing in bacteria, mitochondrial membrane fusion / apoptosis
(PARL) and stem cell differentiation in eukaryotes (3;4). Also, rhomboid-like proteins have
been recently linked to human disease, including early-onset blindness, diabetes, and parasitic
diseases (5). However, the biological functions of the mammalian rhomboid-like family remain
to be determined.
Here we present data supporting the role of RHBDD2 as a novel breast cancer related gene.
We demonstrate that RHBDD2 is over-expressed at the mRNA and protein level in breast
cancer samples and in some of these cases due to gene amplification. Interestingly, analysis of
publicly available breast cancer gene expression databases indicates that RHBDD2 is over-
expressed in estrogen receptor-negative breast carcinomas from patients with poor prognosis.
Finally, we show that in vitro RHBDD2 silencing regulates cell proliferation of breast cancer
cells.
MATERIAL AND METHODS
Serial analysis of gene expression database mining
To perform a comparative analysis of the human Rhomboid-like family members expressed
in breast tissue, we analyzed 46 breast SAGE (serial analysis of gene expression) libraries: 4
normal breast epithelium, 8 ductal carcinoma in situ (DCIS), 33 invasive ductal carcinomas
(IDC). To this end, we combined 29 breast cancer SAGE libraries generated by us at a
resolution of 100,000 tags per library (Aldaz Laboratory) with 17 SAGE libraries (generated
at the Polyak Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA) downloaded from
the Cancer Genome Anatomy Project - SAGE Genie database
(http://cgap.nci.nih.gov/SAGE/). SAGE data management and tag-to-gene matching for
RHBDD1 (AGGGCAGGGA), RHBDD2 (TTGTCTGCCT), RHBDD3 (CTGCCCTAGT),
RHBDL1 (TGGTGGCCGC), RHBDL2 (AGTTCAAGAC), RHBDL3 (TTGCTCCCCG),
RHBDF1 (TGGCCAATAA), RHBDF2 (GATTAAATAA), and PARL (GCTATGCTCC)
were performed with a suite of web-based SAGE library annotation tools developed by us
(http://spi.mdacc.tmc.edu/bitools/about/sage_lib_tool.html). To enable the visualization and
illustration of our analyses, we used the TIGR MultiExperiment Viewer (MeV 3.0) software
(The Institute for Genomic Research, Rockville, MD, USA). This tool was employed for
normalization and average clustering of the SAGE data.
RHBDD2 antibody production, Western-blot and immunofluorescence analyses
A polyclonal antibody against RHBDD2 was generated by sequential immunizations of two
rabbits with three purified KLH-conjugated peptides (GenScript Corp., NJ, USA). Peptides
were synthesized based on RHBDD2 protein sequence (NP065735) corresponding to residues
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30-43 (EDRQPASRRGAGTT), residues 253-266 (ASGAEARSDLPLQP), and residues
393-406 (HQGLQAPRSPPGSP). The polyclonal antibody was purified from the immune
serum by affinity chromatography. The primary antibody specificity was further demonstrated
by western-blot, immunofluorescence and siRNA analyses using breast cell lines (see below
Fig. 2 and Fig. 6B).
Total protein extracts were prepared from a set of 7 breast normal and cancer cell lines (HME87,
MCF10, MCF7, ZR75-30, T47D, BT47A, BT549). As normal controls we also included human
breast epithelial organoids protein extracts, obtained from three independent cosmetic
mammoplastic specimens (B26, B27, B28). Total cell protein lysates were made from frozen
tissues using RIPA buffer (50 mM Tris pH7.5, 150 mM NaCl, 0.5% sodium deoxycholate, 1%
Triton X-100, 0.1% SDS) containing protease inhibitor cocktail (Roche, Mannheim,
Germany). For Western-blot, 50 ug of total protein was separated by 12.5% SDS-PAGE and
transferred to PVDF membranes (Millipore, Billerica, MA). Immunodetection was performed
using Protein Detector™ (KPL, Gaithersburg, MD) western blotting reagents as described by
the manufacturer. RHBDD2 protein was detected using an anti-RHBDD2 polyclonal primary
antibodies and HRP conjugated anti-rabbit secondary antibody (KPL, 1:2000) followed by
chemiluminescence autoradiography. Beta-actin protein (ACTB) was detected using
monoclonal anti-actin antibody (ICN Biomedicals, Burlingame, CA, 1:1000) and HRP
conjugated anti-mouse secondary antibody (KPL, 1:5000).
For immunofluorescence analysis, MCF7 and MCF10 smears from exponentially growing
cells were prepared on glass slides and then fixed in cold acetone for 10 min. Anti-RHBDD2
polyclonal antibody was added to the slides at a 1:250 dilution, and incubated at room
temperature during 1 hour. Detection was performed using FITC-labeled secondary anti-rabbit
IgG antibodies following standard immunofluorescence methods.
RT-PCR and cDNA sequencing analyses
Total RNA was isolated from eleventh frozen normal breast tissue derived from cosmetic
mammoplastic specimens and three breast cancer cell lines (MCF7, T47D and ZR75) using
TRI reagent® (MCR Inc., USA). Quality control of RNA integrity was made by running out
RNA samples onto formaldehyde denaturing 1.2% agarose gel and ethidium bromide staining.
Followed to DNAse I digestion, template cDNAs was synthesized using SuperScript™ First-
strand Synthesis System (Invitrogene, USA). For mRNA expression analysis, we designed
three combinations of PCR primers (Forward-1/Reverse, Forward-2/Reverse, and Forward-3/
Reverse) that spanned all exons of the RHBDD2 transcript. The primers sequences are as
follows: Forward-1 5′-CATCCGCCACCTTCTTCACT-3′; Forward-2 5′-
GATCTTCGCCATCTTCTCCG-3′; Forward-3 5′-GCCTGATGAGGAGGATATCCG-3′;
and Reverse 5′-AATACACCGTGCCAGGGCT-3′.
The isolated RT-PCR products were sequenced in both directions using the DYEnamic ET
Dye Terminator Cycle Sequencing Kit and analyzed on a MEGABACE 1000 DNA sequencer
(GE Healthcare Biosciences), according to the manufacturer’s instructions. The obtained DNA
sequences were further aligned and compared with the RHBDD2 genomic sequence (accession
no. NT 007933.14) to determine the exon-intron structure of RHBDD2. Experiments were
performed in triplicate for each data point and beta-actin (ACTB) mRNA was used as reference.
Inmunohistochemistry analyses of RHBDD2 protein expression in tissues
Formalin-fixed paraffin-embedded breast tissue samples were obtained from the MD Anderson
Cancer Center - USA (61 samples), and at different hospitals associated to the National
University of La Plata - Argentina (152 samples). The use of human tissue blocks and clinical
records was approved by the appropriate institutional Committees. By pooling both sample
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sets we were able to analyze a total of 213 cases including: 44 normal breast tissues (18 normal
tissues from individuals without breast cancer, and 26 normal tissues adjacent to invasive breast
cancers), 18 benign breast disease (7 benign mammary dysplasia, and 11 breast
fibroadenomas), 26 ductal carcinomas in situ (DCIS), 109 primary invasive ductal carcinomas
(IDC) and 16 lymph node metastases specimens (LNM). Stage at time of diagnosis was based
on the TNM classification.
Prior to immunostaining, endogenous peroxidase activity was blocked with 3% H2O2 in water
for 10 min; heat-induced epitope retrieve was performed with 10 mM Citrate buffer pH 6.0 for
10 min in a microwave oven followed by a 20 min cool down. In order to block non-specific
antibody binding, the slides were incubated with 10% goat serum in PBS for 30 min. Primary
polyclonal RHBDD2 antibody was used at 1:250 dilution. Inmunodetection was performed
with the DakoCytomation LSAB+ System-HRP (Dako, Denmark). Sections were
counterstained with hematoxylin (Sigma, USA) and examined by light microscopy. Staining
intensity was graded as negative (-), weak (+), moderate (++), or strong (+++). The number of
optical fields in a specimen that were positively stained was expressed as a percentage of the
total number of optical fields containing tissue. A reaction was considered positive when more
than 5% of the breast epithelial cells were stained. The staining of cytoplasm, plasma membrane
and nucleus was evaluated; cells were considered positive when at least one of these
components was stained. IHC analysis of ESR1 ERα was performed by using a primary
monoclonal ERα antibody (ER-6F11, Novocastra - UK) at 1:50 dilution as was previously
described (6).
RHBDD2 gene amplification analysis
DNA was isolated from 131 formalin-fixed paraffin-embedded samples (17 normal samples,
16 benign lesions and 98 invasive breast carcinomas) previously analyzed for RHBDD2 protein
expression by IHC. RHBDD2 gene amplification was estimated using a competitive PCR
method (7;8). In the duplex PCR reactions, RHBDD2 gene located at 7q11.23, and Solute
carrier family 13A1 gene (SLC13A1, gene not known to be associated with cancer) located at
7q31-q32, is used as the intra-chromosomal arm reference gene. SLC13A1 was chosen as
reference gene due its chromosome location (7q31-32) is losses in less than 2% of breast cancer
cases based on array-CGH Progenetix database (9). Duplex PCR amplification was done in a
final volume of 50 ul using 10ng of cDNA, 1.25 units of Taq DNA polymerase (Promega,
Madison, Wisconsin - USA), 2.5 mM MgCl2, 200 mM of each dNTP and 12.5 pmol of both
primers pairs in PCR buffer (20 mM, Tris-HCL pH8.4, 50 mM KCL). The primers for both
genes are RHBDD2-forward 5′-CATCCGCCACCTTCTTCACT-3′, RHBDD2-reverse 5′-
TGGTGATGAGGACCGAGACA-3′ (amplicon of 259 bp), SLC13A1-forward 5′-
TCGCCGATTTCTCTTCGTG-3′ and SLC13A1-reverse 5′-
GCCAGGCAGTTAAACAGCAAA-3′ (amplicon of 157 bp). The reactions were cycled as
follows: 1 cycle of 94°C for 2 min; 25 cycles of 40” at 92°C, 40” at 57°C, 40” at 72°C. Detection
of the amplified fragments was made by electrophoresis onto a 2% agarose gel and SYBR-
Safe™ DNA staining (Invitrogen - USA). The Kodak Digital Science 1D Image Analysis
Software was used to determine the ratio between net intensity bands of RHBDD2 and
SLC13A1 amplicons. Samples were considered to be affected by genomic amplification for
RHBDD2 when the ratio between net intensity bands was greater than +3SD (99% confidence
interval, p<0.001) relative to the average value determined from 11 normal breast control
samples. Experiments were performed in triplicate for each data point.
In silico RHBDD2 gene expression and clinical data analysis
To further investigate correlations of transcriptional up-modulation of RHBDD2 gene and
clinicopathologic parameters on larger breast carcinoma sets, data were obtained from a
publicly available breast cancer microarray study (10). Clinicopathologic and gene expression
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data from 295 primary invasive breast carcinomas (226 ER-positive and 69 ER-negative
carcinomas) were collected from the Rosetta Inpharmatics website
(http://www.rii.com/publications/2002/nejm.html). Two groups of patients were derived by
using the median expression value of the Log2 ratio overall distribution for RHBDD2 probe
(NM_020684) (RHBDD2 median =0.017; high expression, greater than 0.017; and low
expression, less than 0.017). Kaplan-Meier analysis was assessed with both groups using the
Van de Vijver et al. data by means of SPSS® statistic software (SPSS Inc., Chicago).
RHBDD2 gene silencing and cell proliferation assay
Three siRNAs of 19-mer against RHBDD2 mRNA corresponding to coding sequences starting
at positions 1326 (siRNA-R1: 5′-CUGUGUUGGGUACUUUGAUdTdT-3′), 340 (siRNA-R2:
5′-GUCUACGAGAAUCCCAUCUdTdT-3′) and 1050 (siRNA-R3: 5′-
GCAGAACCACUUUGGUCCAdtdt-3′) relative to the cDNA sequence AF226732 were
synthesized (Bioneer Inc, Korea). The AccuTarget™ biotin-labeled negative control siRNA
(siRNA-NegCt: 5′-CCUACGCCACCAAUUUCGUdTdT-3′) (Bioneer Inc, Korea) that
exhibit no homology to any human genome sequence was used as non-silencing reference. In
addition, we included a positive control siRNA sequence (Termo Scientific Dharmacon, USA),
which significantly reduce the lamin A/C protein level by >70% without affecting the MCF7
cell phenotype or viability. MCF7 cells were seeded on 12 well plate format in Opti-MEM I
Reduced Serum Medium (Invitrogen, USA), when cells reached 40% confluence, they were
transfected with 40 pmoles/ul of siRNA mixed with TransIT-TKO® Transfection Reagent
according to the manufacturer’s protocol (Mirus, USA). Transfection efficiency was monitored
using biotinylated siRNA and FITC-avidin for detection. RHBDD2 mRNA and protein levels
and effects on cells were analyzed by RT-PCR and immunofluorescence at 48 hs post-
transfection respectively. Cell proliferation was assessed using the CellTiter 96® Aqueous
Non-Radioactive Cell Proliferation Assay (Promega, USA), that is a colorimetric method for
determining the number of viable cells in proliferation. In addition, cell viability was monitored
daily by the trypan blue exclusion test.
Additional bioinformatics and statistical analyses
We employed the ASAP on-line database resource (Alternative Splicing Annotation Project)
for the in silico analysis of RHBDD2 exon-intron structure
(http://www.bioinformatics.ucla.edu/ASAP). ASAP is based on human genome-wide analyses
of alternative splicing events based on detailed aligment of EST/cDNA sequences onto the
genomic sequence (11).
To enable visualization and illustration of the 7q11.2 chromosome region in some breast cancer
cell lines from Pollack’s array-CGH data (12), we used the VAMP software (Visualization and
Analysis of array-CGH, transcriptome and other Molecular Profiles)
(http://bioinfo-out.curie.fr/actudb). VAMP is a graphical user interface for visualization and
analysis of genomic profiles (13). The chromosome 7 array-CGH profiles previously generated
by Pollack et al. (12) from MCF7, T47D and ZR75 breast cancer cell lines were download
from the ACTuDB database at the same website (14). The frequency of DNA gains/losses
affecting the chromosome region 7q11.23 was determined from a cumulative set of 552 IDC
analyzed by array-CGH based on a publicly available Progenetix database
(http://www.progenetix.net) (9).
Univariate analysis of clinical-pathological parameters based on RHBDD2 gene amplification /
expression were determined by Fisher’s exact test. Ordinal-by-ordinal associations have been
assessed by Kendall’s tau-b test. The basic significance level was fixed at p< 0.05 and all data
were analyzed using SPSS® statistic software (SPSS Inc., Chicago).
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RESULTS
Human rhomboid family members expressed in breast epithelial cells
We analyzed the rhomboid-like family members gene expression profile in a set of normal and
breast cancer SAGE libraries. Among the rhomboid family members, RHBDD2 and
RHBDF1 were the most frequently expressed rhomboid-like genes in breast SAGE libraries
(Figure 1A). Specifically, RHBDD2 was detected as being expressed in 100% of breast cancer
cases (34 out of 34) according to SAGE database analyses. Interestingly, among the rhomboid
genes only RHBDD2 was identified as over-expressed in primary invasive breast carcinomas
compared with normal breast samples (p<0.008) (Figure 1B). No association was detected
between the expression of this transcript and ERαstatus (p>0.05).
RHBDD2 expression analysis in normal and breast cancer cell lines and identification of
alternatively spliced mRNA isoforms
We performed Western-blot analysis in normal and breast cancer cell lines using a custom-
design polyclonal antibody against the RHBDD2 protein. We identified the expected 47 Kda
product as well as a smaller protein product at approximately 40 Kda. MCF7 and T47D cell
lines showed high levels of RHBDD2 protein expression, while normal breast organoids (B26,
B27, and B28) and non-transformed breast cell lines (MCF10A and HME87) showed weak
and undetectable levels of RHBDD2 protein expression respectively (Fig. 2A). RHBDD2
immunostaining displayed a granulate / vesicular pattern compatible with and endoplasmic
reticulum-like distribution with accumulation in the perinuclear space of MCF7 and T47D cells
(Fig. 2B and Supplementary Fig. 1). MCF10 cells smears were used as the negative control of
the reaction demonstrated non cross-reactivity of the primary antibody (Fig. 2B).
We decided to investigate whether the different protein products were results of alternatively
spliced RHBDD2 transcripts (isoform). RHBDD2 alternative splicing prediction based on
ASAP (Alternative Splicing Annotation Project) bioinformatics analysis revealed two putative
isoforms, here named as isoform 1 (full-length RHBDD2 mRNA) and isoform 2 (alternatively
spliced isoform) (Fig. 3A). To validate these findings, we first performed a RT-PCR analysis
in MCF7, T47D and ZR75 breast cancer cell lines. Three pairs of PCR primers, based on EST
sequences were used to amplify the RHBDD2 transcript from cDNA, and the products were
sequenced. MCF7 and T47D cell lines showed high expression levels of RHBDD2 with any
combination of PCR primers used for RT-PCR analysis (Fig. 3B, 3C). Interestingly, primer
pairs F1 / R located on the first and last exons of RHBDD2 mRNA respectively, results in two
PCR products of approximately 1100 and 900 bp in MCF7 and T47D cell lines (Fig. 3A). The
luminal-tumor derived cell line ZR75 showed weak RHBDD2 mRNA expression. However,
primer pairs F2 / R and F3 / R results in a unique RT-PCR product of 720 bp and 369 bp
respectively as it was expected (Fig 3B, 3C) and confirmed by direct DNA sequencing (data
not shown). Bi-directional sequence analysis was performed on each purified RT-PCR
products from the MCF7 cell line. Comparison of these sequences with the publicly available
RHBDD2 genomic sequence (accession no. NT 007933.14) confirmed gene identity for each
PCR fragment and revealed that these two transcripts detected with the primer pairs F1/R were
generated by alternative RNA splicing of exons 1 and 2 of RHBDD2 (Fig. 3D). These data
suggest that the low protein product observed in the Western-blot analysis represents true
RHBDD2 protein, demonstrating that the antibody used in our study detected the full-length
RHBDD2 protein (isoform 1) as well as the alternative splicing variant (isoform 2) (Fig. 2). In
addition, this RT-PCR analysis showed undetectable or low expression of RHBDD2 gene in
normal breast tissues analyzed (Fig 3C). These data corroborate the SAGE analysis showing
that RHBDD2 mRNA / protein expression is highly elevated in some breast cancer cells
compared with normal breast samples.
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Increased RHBDD2 protein expression in breast cancer clinical specimens
To further investigate the relevance of RHBDD2 protein expression in breast cancer, we
analyzed 213 breast tissue sections by inmunohistochemistry (Table 1 and Figure 4). We
identified a statistical significant increase in RHBDD2 protein expression from normal breast
tissues to breast cancer metastases specimens analyzed (p-trend=0.01).
RHBDD2 protein expression was detected in 61% (27 out of 44) of normal breast samples
analyzed. Interestingly, 95% (17 out of 18) of normal breast epithelium obtained from cosmetic
mammoplasties, showed negative or weak RHBDD2 protein expression (Table 1). In contrast,
69% (18 out of 26) of normal breast tissue adjacent to invasive ductal carcinomas showed
moderate or strong RHBDD2 expression, and only 31% (8 out of 26) of these samples showed
negative or weak RHBDD2 inmunostaining (Table 1). Statistical analysis of RHBDD2 protein
expression between normal breast epithelium and normal breast adjacent IDC showed highly
significant differences (p=0.0001). RHBDD2 inmunostaining showed a granulate reaction that
was mostly localized in the perinuclear space and in the membrane.
Benign mammary dysplasia and fibroadenoma lesions displayed negative or weak RHBDD2
protein expression in approximately 66% (12 out of 18) of the analyzed cases, while moderate
or strong RHBDD2 protein expression was predominantly detected in 69% (18 out of 26) of
the ductal carcinomas in situ analyzed (p<0.01) (Table 1).
Among IDC samples, negative RHBDD2 expression was detected in 28% of the cases (31 out
of 109). However, when RHBDD2 expression and tumor stage were considered, we observed
a statistically significant correlation between high levels of RHBDD2 and more clinically
advanced cancer (p=0.001). In this sense, 92% of IDC negative for RHBDD2 expression were
early-stage (I and II) breast carcinomas while only 9% of tumors stage III were negative for
RHBDD2 protein expression. Furthermore, 50% of IDC with tumor stage III showed moderate
or strong RHBDD2 protein expression. Interestingly, RHBDD2 protein expression was
detected in all breast lymph node metastases samples (16 out of 16) displayed a moderate or
strong RHBDD2 expression in approximately 75% (12 out of 16) of the analyzed samples
(Table 1 and Figure 4). Non-statistical significant association was detected between RHBDD2
protein expression and ERαstatus as well as histologic tumor grade (p>0.05).
Overall, these data are in agreement with the SAGE profiling analysis, indicating that a high
proportion of invasive breast carcinomas expressed significantly increased levels of RHBDD2
protein compared with normal breast samples. More importantly, strong RHBDD2 protein
expression was highly associated with primary invasive breast carcinomas with axillary lymph
node metastases.
RHBDD2 gene is amplified in correlation with over-expression in breast cancer cells
Microarray-based comparative genomic hybridization evidence is available reporting the
amplification of the chromosomal region 7q11.23 in breast cancer cell lines and primary breast
carcinomas (12;15). To investigate the frequency of DNA gains/losses affecting the
chromosome region 7q11.23, we performed a pooled re-analysis of 552 invasive breast
carcinomas previously analyzed by array-CGH, available at Progenetix online database.
Pooled estimates showed gain of chromosome region 7q11.23 in 11% of the analyzed cases
(61 out of 552 IDC). The Visualization and Analysis of array-CGH, transcriptome and other
Molecular Profiles (VAMP) (13) resource was employed for microarray-CGH data analysis
of chromosome region 7q11.23 from MCF7, T47D and ZR75 breast cancer cell lines. In
silico analysis of Pollack’s data (14) identified a gain of chromosome region 7q11.22 - 7q11.23
including the RHBDD2 gene region in MCF7 and T47D cell lines (Fig. 5A). These data are in
agreement with our western blot observations.
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We used a competitive PCR method based on duplex PCR of RHBDD2 (target) and
SLC13A1 (control) genes for the quick interrogation of human breast tumor DNA for the
presence or absence of genomic amplification of specific genes affecting the region of interest.
We analyzed DNA obtained from breast cancer cell lines and 131 samples (17 normal tissues,
16 benign lesions, 98 IDC) previously analyzed for protein expression by IHC. The DNA from
all samples were adequately amplified by the SLC13A1 control primers. Competitive PCR
analysis showed RHBDD2 gene amplification in MCF7 and T47D breast cancer cell lines,
while no amplification was detected for the ZR75 cancer line, in agreement with the array-
CGH data and validating the method (Fig. 5B). It is important to note, that RHBDD2 mRNA
and protein expression are highly elevated in both breast cancer cell lines (MCF7 and T47D),
thus confirming a direct association between RHBDD2 gene amplification and over-
expression. RHBDD2 genomic amplification was detected in 21% (21 out of 98) primary
invasive breast carcinomas analyzed (Fig. 5D). However, no amplification in RHBDD2 was
identified in any of 17 normal and 16 benign tissue samples analyzed. Statistical analysis
identified a significant positive association between RHBDD2 gene amplification and
RHBDD2 protein expression assessed by IHC studies (p<0.05).
RHBDD2 gene silencing in vitro leads to reduced cell proliferation rate
To investigate whether RHBDD2 gene expression plays any role associated to cell
proliferation; a knock-down assay was performed with specific siRNA sequences targeting
RHBDD2 mRNA in MCF7 breast cancer cell line. Cells were treated with optimal
concentrations of RHBDD2 siRNA and examined the number of viable cells 48 hours after
transfection.
RT-PCR and immunofluorescence analyses demonstrated an effective depletion of RHBDD2
at mRNA and protein level in MCF7 by using the siRNA-R1 and siRNA-R3 sequences
compared with the negative control siRNA (Fig. 6A and 6B). MCF7 cells in the control group
were treated with the siRNA-Ct, which had a randomized nucleotide sequence that had no
significant homology to the human genome. siRNA-R1 and siRNA-R3 treated cells showed a
significant decrease in cancer cell proliferation 48 hours after transfection compared to negative
or positive control siRNAs (Fig. 6C). In addition, siRNA-R1 and siRNA-R3 treatments did
not affect cell viability or morphology of MCF7 breast cancer cells. This result suggests that
RHBDD2 function is related to regulation of cell proliferation in MCF7 breast cancer cells.
RHBDD2 expression analysis and it clinical relevance as poor-prognosis marker
To further explore the clinical relevance of gene expression in human breast carcinomas, we
evaluated information from publicly available breast cancer gene expression datasets
(microarrays). Because the estrogen receptor plays a critical role in breast cancer, we first
analyzed gene expression profiles of RHBDD2 relative to ERαstatus. Statistical analysis
showed that RHBDD2 expression was not associated with ERαstatus of primary breast
carcinomas (p=0.148). This result is in agreement with our previously described data regarding
RHBDD2 gene / protein expression in primary breast carcinomas obtained by SAGE and IHC
studies.
Next, we analyzed RHBDD2 expression with patient’s outcome using the microarray data set
of Van de Vijver et al., 2002. Interestingly, we identified a significant association between
high-expression of RHBDD2 and short time relapse-free survival among 295 patients (p=0.018;
Fig. 7A). Kaplan-Meier analysis revealed that RHBDD2 over-expression was particularly
associated with shorter overall survival (p=0.0023; Fig. 7B), metastasis-free interval (p=0.006;
Fig. 7C), and relapse-free survival (p=0.013; Fig. 7D) but surprisingly only in patients with
ERα-negative breast carcinomas. Non-statistical significant associations were found for
RHBDD2 expression and follow-up in patients with ERα-positive carcinomas (p>0.05).
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DISCUSSION
In a recent study using SAGE, we performed a comparative global gene expression profile of
primary invasive breast carcinomas (1). Unsupervised statistical analysis identified two main
breast carcinomas clusters which differed in their lymph node status, suggesting that lymph
node status leads to a global distinct expression profile. In this study, we identified a rhomboid-
like family member gene known as RHBDD2 to be up-regulated in lymph node (+) breast
carcinomas compared with lymph node (-) counterparts. Real-time RT-PCR analysis of an
independent set of breast carcinomas demonstrated statistically significant RHBDD2 over-
expression in the primary breast cancers from patients that recurred within 6 years of follow-
up (1).
In the present study, we first determined the human rhomboid-like family members gene
expression profile in a set of 46 normal and breast carcinoma SAGE libraries. We found that
the RHBDD2 transcript was readily detectable in almost all primary invasive breast carcinoma
and over-expressed compared to normal breast samples. In addition, a second human
rhomboid-like gene, RHBDF1 (Rhomboid family-1 gene), was identified as highly expressed
in primary invasive breast SAGE libraries. Interestingly, in a recent study Yan et al., 2008
showed that RHBDF1 is significantly elevated in invasive ductal carcinomas at both mRNA
and protein levels, and also seems important for breast cancer cell growth in vivo and in vitro
(16).
We further explored RHBDD2 protein expression in 213 breast tissue samples by
immunohistochemistry. This study confirmed the SAGE observations, showing that RHBDD2
protein is highly expressed in primary invasive breast carcinomas stage III and lymph node
metastasis. However, this study also found that RHBDD2 was highly expressed in some DCIS,
suggesting that RHBDD2 expression may occur early in the development of cancer.
Interestingly, we detected that normal breast tissue adjacent to invasive breast carcinomas
showed moderate or strong RHBDD2 expression while normal breast epithelium from
mammoplasty specimens showed to be predominantly negative for RHBDD2 expression. This
observation of abnormal high RHBDD2 expression in mammary epithelium adjacent to cancer
allows us to speculate that expression of this protein could be influenced by the tumor
microenvironment. It is possible that autocrine or paracrine stimuli maybe operative in
modulating RHBDD2 expression in mammary epithelial cells.
Tumor-specific up-regulation of some genes can be attributed to aberrant DNA amplification,
a phenomenon frequently found in many breast tumors (12). Usually genomic amplification
in cancer involves genes that provide some sort of growth advantage or transformation to the
cells bearing the amplification. Typically amplification involves growth factors, growth factor
receptors, certain cyclins, transcription factors or co-activators, i.e. positive regulators of
proliferation and by definition many are dubbed oncogenes. Interestingly, microarray-based
comparative genomic hybridization evidence is available reporting amplification of the
chromosomal region 7q11.2 (the same region to which RHBDD2 maps) in breast cancer cell
lines and primary breast carcinomas (12;15). Moreover, a genome-wide transcriptome map
revealed clusters of genes located at 7q11.2 exhibiting non-random increased expression in
breast cancer cells (17). To determine whether RHBDD2 was also amplified and over-
expressed in breast tumors, we studied 98 primary invasive breast carcinomas for gene
amplification and protein expression by RG-PCR and IHC respectively. RHBDD2 was
amplified in 21% of the analyzed samples. Although, almost all amplified samples showed
moderate to strong RHBDD2 protein expression, some breast carcinomas showed over-
expression of RHBDD2 in the absence of gene amplification, suggesting in addition up-
regulation of expression by transcriptional regulatory means. We also determined that
RHBDD2 over-expression in cell lines MCF7 and T47D was likely the result of amplification
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of chromosome region 7q11.23. In addition, we identified and characterized the expression of
two alternative spliced RHBDD2 mRNA isoforms in these breast cancer cell lines.
Interestingly, in a recent study Yan et al., 2008, demonstrated that abrogation of RHBDF1
expression in MDA-MB435 cells or head and neck squamous cancer cell line 1483 leads to
inhibition of cell proliferation. siRNA mediated RHBDF1 silencing results in apoptosis in
breast cancer cells and inhibition of xenograft tumor growth in vivo (16). More importantly,
in a very recently study Zou et al., 2008, demonstrated that RHBDF1 participates in the
modulation of G protein-coupled receptors-mediated EGFR transactivation. Furthermore,
RHBDF1 over-expression in head and neck cancer cells results in facilitated export of TGFα
(18). These data suggest that the RHBDF1 plays a critical role in the mechanism responsible
for the production of activated EGFR ligand. Similarly to the observations of Yan et al in our
studies we found that siRNA-mediated silencing of RHBDD2 expression in MCF7 breast
cancer cell line lead to a marked decrease in cell proliferation. Thus, the possibility exists that
RHBDD2 may also play a role in signaling pathways related to cell proliferation / survival as
shown for RHDBF1; as such it could be a protein of relevance in breast cancer initiation and
progression. Interestingly, and supporting this speculation, in silico analyses revealed that
patients whose tumors expressed high RHBDD2 had significantly shorter relapse-free survival
when compared with those whose tumors had low RHBDD2 levels. More importantly, we
found that high RHBDD2 expression was significantly associated with shorter overall survival,
relapse-free survival, and metastasis-free interval in patients with ERα-negative breast
carcinomas. These data are in line with our observation that increased RHBDD2 protein
expression is associated with advanced tumor stages. In addition, we further confirmed our
initial finding in which we observed a statistical significant over-expression of RHBDD2 in
primary tumors of patients that after follow up developed recurrent disease (1). In summary,
our findings indicate that RHBDD2 over-expression might play a role in breast cancer tumor
progression facilitating the development of more aggressive phenotypes in at least a subset of
breast carcinomas. Further studies are required to elucidate the exact role of this protein in
breast cancer.
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Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
The authors gratefully acknowledge Dr Aysegul Sahin (Department of Pathology, MD Anderson Cancer Center,
Houston - TX), who kindly provided some breast cancer samples. This work was supported by FONCYT (PICT N°
32702, BID 1728 OC/AR), CONICET (PIP N°112-200801-02131), and NIH-NCI (1U19 CA84978-1A1) grants.
REFERENCES
1. Abba MC, Sun H, Hawkins KA, Drake JA, Hu Y, Nunez MI, et al. Breast cancer molecular signatures
as determined by SAGE: correlation with lymph node status. Mol Cancer Res 2007;5(9):881–90.
[PubMed: 17855657]
2. Lemberg MK, Freeman M. Functional and evolutionary implications of enhanced genomic analysis
of rhomboid intramembrane proteases. Genome Res 2007;17(11):1634–1646. [PubMed: 17938163]
3. Jeyaraju DV, Xu L, Letellier M, Bandaru S, Zunino R, Berg EA, et al. Phosphorylation and cleavage
of presenilin-associated rhomboid-like protein (PARL) promotes changes in mitochondrial
morphology. Proc Natl Acad Sci U S A 2006;103(49):18562–7. [PubMed: 17116872]
4. Cipolat S, Rudka T, Hartmann D, Costa V, Serneels L, Craessaerts K, et al. Mitochondrial rhomboid
PARL regulates cytochrome c release during apoptosis via OPA1-dependent cristae remodeling. Cell
2006;126(1):163–75. [PubMed: 16839884]
Abba et al. Page 10
Biochim Biophys Acta. Author manuscript; available in PMC 2010 October 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
5. Urban S. Rhomboid proteins: conserved membrane proteases with divergent biological functions.
Genes Dev 2006;20(22):3054–68. [PubMed: 17114579]
6. Abba MC, Hu Y, Sun H, Drake JA, Gaddis S, Baggerly K, et al. Gene expression signature of estrogen
receptor alpha status in breast cancer. BMC Genomics 2005;6(1):37. [PubMed: 15762987]
7. Abba MC, Laguens RM, Dulout FN, Golijow CD. The c-myc activation in cervical carcinomas and
HPV 16 infections. Mutat Res 2004;557(2):151–8. [PubMed: 14729369]
8. Abba MC, Fabris VT, Hu Y, Kittrell FS, Cai W, Donehower LA, et al. Identification of novel
amplification gene targets in mouse and human breast cancer at a syntenic cluster mapping to mouse
ch8A1 and human ch13q34. Cancer Res May 1;2007 67(9):4104–12. [PubMed: 17483321]
9. Baudis M, Cleary ML. Progenetix.net: an online repository for molecular cytogenetic aberration data.
Bioinformatics 2001;17(12):1228–9.Progenetix.net [PubMed: 11751233]
10. van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AAM, Voskuil DW, et al. A gene-expression
signature as a predictor of survival in breast cancer. N Engl J Med 2002;347(25):1999–2009.
[PubMed: 12490681]
11. Lee C, Atanelov L, Modrek B, Xing Y. ASAP: the Alternative Splicing Annotation Project. Nucleic
Acids Res 2003;31(1):101–5. [PubMed: 12519958]
12. Pollack JR, Sørlie T, Perou CM, Rees CA, Jeffrey SS, Lonning PE, et al. Microarray analysis reveals
a major direct role of DNA copy number alteration in the transcriptional program of human breast
tumors. Proc Natl Acad Sci U S A 2002;99(20):12963–8. [PubMed: 12297621]
13. La Rosa P, Viara E, Hupé P, Pierron G, Liva S, Neuvial P, et al. VAMP: visualization and analysis
of array-CGH, transcriptome and other molecular profiles. Bioinformatics 2006;22(17):2066–73.
[PubMed: 16820431]
14. Hupé P, La Rosa P, Liva S, Lair S, Servant N, Barillot E. ACTuDB, a new database for the integrated
analysis of array-CGH and clinical data for tumors. Oncogene 2007;26(46):6641–52. [PubMed:
17496932]
15. Forozan F, Mahlamäki EH, Monni O, Chen Y, Veldman R, Jiang Y, et al. Comparative genomic
hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA
microarray data. Cancer Res 2000;60(16):4519–25. [PubMed: 10969801]
16. Yan Z, Zou H, Tian F, Grandis JR, Mixson AJ, Lu PY, et al. Human rhomboid family-1 gene silencing
causes apoptosis or autophagy to epithelial cancer cells and inhibits xenograft tumor growth. Mol
Cancer Ther 2008;7(6):1355–64. [PubMed: 18524845]
17. Zhou Y, Luoh S, Zhang Y, Watanabe C, Wu TD, Ostland M, et al. Genome-wide identification of
chromosomal regions of increased tumor expression by transcriptome analysis. Cancer Res 2003;63
(18):5781–4. [PubMed: 14522899]
18. Zou H, Thomas SM, Yan Z, Grandis JR, Vogt A, Li L. Human rhomboid family-1 gene RHBDF1
participates in GPCR-mediated transactivation of EGFR growth signals in head and neck squamous
cancer cells. FASEB J 2009;23(2):425–32. [PubMed: 18832597]
Abba et al. Page 11
Biochim Biophys Acta. Author manuscript; available in PMC 2010 October 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
FIGURE 1.
Digital northern analysis of human rhomboid-like family members based on SAGE data in 46
breast samples (4 normal breast epithelium, 8 ductal carcinoma in situ and 34 invasive ductal
carcinomas) (A). The color scale at bottom of picture is used to represent relative expression
level based on numbers of transcripts (tags) per libraries. (B) ANOVA test of RHBDD2
expression among normal breast tissue, ductal carcinoma in situ (DCIS) and primary invasive
breast carcinomas (IDC). High-expression levels of RHBDD2 tag was detected in IDC
compared with normal breast tissue group (p<0.008).
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FIGURE 2.
RHBDD2 protein expression in normal and breast cancer cell lines. (A) Protein extracts were
separated by 12.5% SDS-PAGE and transferred to PVDF membranes. RHBDD2 protein was
detected using a polyclonal anti-RHBDD2 antibody developed by our laboratory. The
membrane was then probed with mouse monoclonal anti-actin antibody for normalization of
differences in protein loading. Three normal human protein extracts prepared from breast
organoids were included (B25, B26, and B27). The full-length RHBDD2 protein (isoform 1)
and the predicted splicing variant (isoform 2) are indicated. (B) Immunofluorescence and
immunocytochemistry detection of RHBDD2 displayed a vesicular pattern compatible with
an ER-like distribution in MCF7 cells (see Supplementary Figure 1). MCF10 cells smears were
used as the negative control demonstrated non cross-reactivity of the primary antibody. MCF7
cells without RHBDD2 polyclonal antibody was also used as negative control of the reaction
(MCF7-NegCt). The nuclei were counterstained with propidium iodide (red fluorescence).
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FIGURE 3.
Identification of two RHBDD2 mRNA isoforms. (A) Schematic representation of human
RHBDD2 genomic structure and the corresponding mRNA isoform structure predicted in
silico based on RHBDD2 EST database searching. Alternative splicing involving exons 1 and
2 generates the isoform 2. (B) RHBDD2 RT-PCR of five normal breast tissue (N1-N5) and
three breast cancer cell lines (MCF7, T47D, ZR75). (C) Alignment of the MCF7 cDNA
sequences among RHBDD2 isoforms.
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FIGURE 4.
RHBDD2 immunohistochemical staining in (A) normal breast adjacent tumor (x100), (B)
hyperplastic breast lesion (x100), (C) ductal carcinoma in situ (x400), (D-E) ERα-negative
invasive ductal carcinomas with RHBDD2 gene amplification (x100 and x400 respectively),
and (F) lymph node metastases sample (x400). As negative control for immunohistochemical
staining we used a tissue sample, without primary antibody incubation (G), derived from serial
sections of a RHBDD2-positive invasive breast carcinoma (H).
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FIGURE 5.
RHBDD2 gene amplification analysis in breast samples. (A) Visualization of 7q11.2
microarray-based CGH profile of MCF7, T47D and ZR75 breast cancer cell lines obtained
from Pollack et al., 2002 study. Red lines indicate chromosomal regions of gain. These data
suggest a region of genomic gain located at 7q11.23 involving the RHBDD2 gene. (B) RG-
PCR assay showed RHBDD2 gene amplification in MCF7 and T47D breast cancer cell lines
in agreement with Pollack data. (C) DNA sequence chromatogram of isolated PCR amplicons
confirming the RHBDD2 and SLC13A1 gene sequence identities. (D) RG-PCR analysis in
normal breast tissues (N1-N5), and seven primary invasive breast carcinomas. Note that three
invasive breast carcinomas (samples 996, 1516 and 1495) showed RHBDD2 gene amplification
(black arrows).
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FIGURE 6.
RHBDD2 knock-down analysis in MCF7 breast cancer cell line. (A) RT-PCR analysis of
RHBDD2 and β-actin (ACTB) mRNAs in AccuTarget™ negative control siRNA (siRNA-Ct)
and three RHBDD2 siRNA sequences treatments (siRNA-R1, siRNA-R2 and siRNA-R3).
(B) Immunofluorescence analysis of RHBDD2 protein expression (green fluorescence) in
siRNA-Ct, siRNA-R1 and siRNA-R3 treatments. The nuclei were counterstained with
propidium iodide (red fluorescence). (C) Analysis of relative proliferation rates in MCF7 breast
cancer cells at 48hs after siRNA transfection, expressed as absorbances at 492 nm measured
using the CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay (Promega, USA).
Each point represents the mean ± 2SE of 12 replicates.
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FIGURE 7.
RHBDD2 gene expression profile and breast cancer patients follow-up based on a publicly
available DNA microarray data set. (A) Relapse-free survival of 295 patients grouped
according to low or high RHBDD2 gene expression levels of the primary invasive breast
carcinomas (226 ERα-positive and 69 ERα-negative breast samples). Kaplan-Meier curves of
overall survival (B), metastasis-free interval (C), and relapse-free survival (D) of 69 patients
with ERα-negative primary invasive breast carcinomas based on high or low expression levels
of RHBDD2 gene. Kaplan-Meier analysis was assessed using the Van de Vijver et al, 2002
data set.
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